BioSpace News Archive

Idorsia Ltd and Idorsia Pharmaceuticals Japan announced that PIVLAZ™ is now available to physicians in Japan to start treating aSAH patients.

SNIPR BIOME ApS, a leading CRISPR and microbiome gene therapy biotechnology company, announced dosing of the first human subjects in its phase 1 clinical trial with SNIPR001, an orally administered CRISPR-based therapeutic.

Bavarian Nordic A/S announced the dosing of the first subject in the Phase 3 VANIR clinical trial of its investigational respiratory syncytial virus vaccine candidate, MVA-BN® RSV in older adults.

BioArctic AB has announced that the company’s partner AbbVie has decided to terminate its collaboration with BioArctic regarding the portfolio of alpha-synuclein antibodies, including ABBV-0805.

ANGLE plc, a world-leading liquid biopsy company, will be releasing its preliminary results for the year ended 31 December 2021 on Thursday 28 April 2022.

BioArctic AB will publish the company’s First Quarter Report for January - March 2022 on Thursday, April 28, 2022, at 08:00 a.m. CET.

CLS Americas announced the first patient has been safely treated in its recently announced 20-patient, Phase I clinical study titled, “Targeted MRI/US Fusion Transperineal Laser Ablation of Low-to-Intermediate Risk Prostate Cancer.” The study utilizes CLS’s TRANBERG® Thermal Therapy System in combination with the Focalyx® Fusion medical device for treatment planning, image fusion, and real-time image guidance during the high-precision, focal laser ablation treatment.

Spago Nanomedical AB publishes its interim report for January-March 2022 on Tuesday, 27 April, 2022 at 08.00 CEST.

Samsung Biologics announced that it has completed the purchase of Biogen’s stake in the Samsung Bioepis joint venture for USD $2.3 billion.

Amcor announced the addition of new, more sustainable High Shield laminates to its pharmaceutical packaging portfolio.